Immutep

http://www.immutep.com/

Last activity: 05.03.2024

Active

Categories: ActiveBioTechDevelopmentExchangeHealthTechITMedTechProductResearchTechnology

Australian biotechnology company Immutep Ltd is one of the world's leaders when it comes to cancer treatment. We focus on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are the essentials of what we call the cutting edge of the fight against cancer.

Twitter Facebook LinkedIn Youtube Email

Likes

739

Followers

1.95K

Followers

1.95K

Mentions

Overview

Location

Australia, New South Wales, Sydney

Employees

11-50

Total raised

$48.47M

Founded date

1987

Funding Rounds 3

Date	Series	Amount	Investors
Sign up to see	Sign up to see	Sign up to see	Sign up to see
Jun 21, 2021	Funding round	$45.11M
Apr 16, 2021	Funding round	$898.14K

Mentions in press and media 79

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Dec 7, 2023	Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Jun 27, 2023	Immutep Completes A$80 Million Capital Raise	/EIN News/ -- Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for c...
Jun 27, 2023	Immutep Completes A$80 Million Capital Raise
Sep 23, 2022	Immutep Receives A$2.7 million R&D Tax Incentive from French Government	SYDNEY, AUSTRALIA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune dise...
Feb 11, 2022	Immutep : Granted Australian Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Pd-1 Pathway Inhibitor	ASX/Media Release IMMUTEP GRANTED AUSTRALIAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA - 11 February 2022 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep&q...
Jan 25, 2022	Immutep : Quarterly Activities Report	Media Release Immutep Quarterly Activities Report Final Overall Survival data from AIPAC Phase IIb trial reported at the SITC 2021 conference, supporting Immutep's planned Phase III clinical development of efti in combination with paclitaxe...
Jan 25, 2022	Immutep : Quarterly Activities Report and Appendix 4C	For personal use only ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Final Overall Survival data from AIPAC Phase IIb trial reported at the SITC 2021 conference, supporting Immutep's planned Phase III clinical devel...
Dec 16, 2021	Immutep : Advances IMP761 Manufacturing	ASX/Media Release Immutep Advances IMP761 Manufacturing SYDNEY, AUSTRALIA - 16 December 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3related i...
Dec 2, 2021	Immutep : Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003	ASX/Media Release IMMUTEP REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI STUDY, INSIGHT-003 SYDNEY, AUSTRALIA - 2 December 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Com...
Nov 26, 2021	Immutep : Results of Annual General Meeting	ASX/Media Release RESULTS OF ANNUAL GENERAL MEETING SYDNEY, AUSTRALIA - 26 November 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") advises that the results of its Annual General Meeting (AGM)...
Nov 26, 2021	Immutep : AGM 2021 - Chairman's Address	Immutep AGM 2021 Chairman's Address 26 November 2021 Ladies and Gentlemen, On behalf of the Board, I would like to welcome you to Immutep's Annual General Meeting for the 2021 financial year. Thank you to all our shareholders who join us on...
Nov 22, 2021	Immutep : Goetzpartners securities -Data highlights efti efficacy and potential central role in cancer therapy - Outperform TP to AUD 1.350 (from AUD 0.565) (copy)	IMMUTEP LIMITED Biotechnology 17 November 2021 18:52 GMT FLASH NOTE Immutep Limited (IMM-AU) Data highlights ei eﬃcacy and potenal central role in cancer therapy KEY TAKEAWAY Data presented SITC (Society for Immunotherapy of Cancer) not o...
Nov 19, 2021	Immutep : Phase II TACTI-002-002 trial recruitment successfully completed	ASX/Media Release Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha Enrolled and dosed last patient in the expansion stage of Part A (1st line non-small cell lung cancer (NSCLC)) nee...
Nov 18, 2021	Immutep : Wilsons Equity Research - Immutep Limited (IMM) \| Efti impresses in HNSCC and aids the young & forgotten in metastatic breast cancer	Date Theme 18 November 2021 Company Update Company Immutep Limited (IMM) Efti impresses in HNSCC and aids the young & forgotten in metastatic breast cancer We maintain our OVERWEIGHT recommendation and a $0.91/sh risked PT on Immutep. T...
Nov 18, 2021	Immutep : Maxim Group - AIPAC Presentation at SITC Builds on Prior Data, Prepping to Go Pivotal in mBC	EQUITY RESEARCH COMPANY UPDATE Biotechnology IMMP - NASDAQ November 17, 2021 Closing Price 11/16/21 $4.07 Rating: Buy 12-Month Target Price: $8.00 52-Week Range: $1.75 - $7.95 Market Cap (M): 347.5 Shares O/S (M): 85.4 Float: NA Avg. Daily ...
Nov 16, 2021	Immutep : Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha - Form 6-K	Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha • AIPAC poster presentation includes new data and graphs showing: • Very encouraging Overall Survival (OS) da...
Nov 15, 2021	Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha	AIPAC poster presentation includes new data and graphs showing: Very encouraging Overall Survival (OS) data from the abstract published on 9 November 2021, including statistically significant benefit in 3 patient subgroups representing a ma...
Nov 15, 2021	Immutep : Chinese patent Granted for Efti with PD-1 Pathway Inhibitors	ASX/Media Release IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 FUSION PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA - 15 November 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immut...
Nov 15, 2021	Immutep : announces publication of SITC 2021 posters	For personal use only ASX/Media Release Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha AIPAC poster presentation includes new data and graphs showing: Very ...
Nov 12, 2021	SITC 2021 - TACTI-003 Poster	Abstract # 440 A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC) J A Peguero1, F Triebel2 BACKG...
Nov 12, 2021	Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details - Form 6-K	Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details • Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcemen...
Nov 12, 2021	SITC 2021 - AIPAC Poster	Hans Wildiers1, Anne Armstrong2, Eveline Cuypere3, Florence Dalenc4, Luc Dirix5, Steve Chan6, Frederik Marme7, Carolina Pia Schröder8, Jens Huober9, Jill Wagemans10, Peter Vuylsteke11, Jean-PhilippeJacquin12, Etienne Brain13, Sherko Kümmel1...
Nov 12, 2021	Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha	ASX/Media Release Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha AIPAC poster presentation includes new data and graphs showing: Very encouraging Overall Su...
Nov 9, 2021	Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details	ASX/Media Release Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details Data from Phase IIb AIPAC, including final Overall Survival data, reported in a sepa...
Nov 9, 2021	Late Breaking Abstract for SITC 2021 - AIPAC	Late Breaking Abstract for SITC 2021 - AIPAC Abstract Title: Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC. Background: Eftilag...
Nov 4, 2021	O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	Date Theme 04 November 2021 Initiating Coverage Company Immutep Limited (IMM) O/W: IMMune to failure We initiate on Immutep (IMM) with an OVERWEIGHT recommendation and a $0.91 per share risked PT. Immutep is an Australian clinical stage bio...
Nov 2, 2021	IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A CHEMOTHERAPY AGENT	ASX/Media Release IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A CHEMOTHERAPY AGENT SYDNEY, AUSTRALIA - 2 November 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or ...
Oct 29, 2021	Immutep receives EMA scientific advice in Phase 3 in MBC	ASX/Media Release Immutep receives positive EMA scientific advice for further clinical development of efti in MBC including Phase III Positive feedback for the general clinical development program including the planned registrational Phase ...
Oct 28, 2021	Immutep Quarterly Activities Report & Appendix 4C	ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Received competent authority and institutional review board approvals for TACTI-003 Phase IIb trial Enrolled first patient in INSIGHT-003 study in patients with various...
Oct 25, 2021	Rich Nations Lag Behind in Meeting $100 Billion Climate-Funding Pledge in Blow to COP26
Oct 13, 2021	Immutep : Corporate Connect - A Truly Undervalued Company	Wednesday, 13 October 2021 RESEARCH REPORT Immutep Limited Share Price & Estimated A Truly Undervalued Company Fair Value Price Fair Value Price $2.20 Current Price $0.535 Implied Increase/Dec 311% In May 2021, we published a comprehens...
Sep 29, 2021	Immutep : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)	Immutep Receives A$3.4 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA - 29 September 2021 -Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing...
Sep 29, 2021	Immutep : Receives A$3.4 million R&D French Tax Incentive	ASX/Media Release Immutep Receives A$3.4 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA - 29 September 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology ...
Sep 29, 2021	Immutep : Receives A$3.4 million R&D Tax Incentive from French Government	SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune dise...
Sep 20, 2021	Immutep : Maxim Group - The Case for LAG-3 is Building	EQUITY RESEARCH COMPANY UPDATE Biotechnology Immutep Limited Buy IMMP - NASDAQ September 20, 2021 The Case for LAG-3 is Building Intraday Price 9/20/21 $3.65 Summary Rating: Buy • Could a LAG-3 be the next approved checkpoint? This morning,...
Sep 1, 2021	Immutep : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002	ASX/Media Release Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002 Last 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recr...
Sep 1, 2021	Immutep : PRELIMINARY FINAL REPORT (Form 6-K)	PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2021 Previous corresponding period: Year ended 30 June 2020 2. Results for announcement to the market FY 20...
Aug 31, 2021	Immutep : Partner, EOC Pharma, Expands Efti Trial Pipeline	ASX/Media Release IMMUTEP'S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE SYDNEY, AUSTRALIA - 31 August 2021 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company") is pleased to advise its Chi...
Aug 30, 2021	Immutep : Maxim Group - Annual FY Update; AIPAC Final Data Approaching	EQUITY RESEARCH COMPANY UPDATE Biotechnology IMMP - NASDAQ August 30, 2021 Intraday Price 8/30/21 $3.71 Rating: Buy 12-Month Target Price: $8.00 52-Week Range: $1.22 - $7.95 Market Cap (M): 282.7 Shares O/S (M): 76.2 Float: NA Avg. Daily Vo...
Aug 27, 2021	Immutep : Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525	ASX/Media Release IMMUTEP ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 SYDNEY, AUSTRALIA - 27 August 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), is pleased to annou...
Aug 3, 2021	Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target	Biotechnology Initiating Coverage August 3, 2021 BUY Ahu Demir, Ph.D.; [email protected] 1.561.620.2102 Immutep Ltd. New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target IMMP (NASDAQ) Company & Market Data Clos...
Jul 30, 2021	Immutep : Completion of Placement - Tranche 2	Not for release to US wire services or distribution in the United States ASX/Media Release COMPLETION OF PLACEMENT - TRANCHE 2 SYDNEY, AUSTRALIA - 30 July 2021 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Com...
Jul 21, 2021	Immutep : Completion of Share Purchase Plan	Not for release to US wire services or distribution in the United States ASX/Media Release COMPLETION OF SHARE PURCHASE PLAN SYDNEY, AUSTRALIA - 21 July 2021 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Compa...
Jul 16, 2021	Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT	EQUITY RESEARCH ASSUMPTION OF COVERAGE Biotechnology Immutep Limited Buy IMMP - NASDAQ July 16, 2021 Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Closing Price 7/15/21 $3.53 Checkpoint - Transferring Coverage with a Buy Rati...
Jul 14, 2021	Immutep : Bell Potter - Creating Value with Phase 3 around the corner – Increasing TP to AUD 1.00 (from AUD 0.85)	Speculative 14 July 2021 See Key Risks on Page 10 &11 & Biotechnology Risk warning on Page 13 Speculative securities may not be suitable for Retail clients Analyst Tanushree Jain 612 8224 2849 Authorisation John Hester 612 8224 2871...
Jun 22, 2021	Immutep : completes a A$60 million placement to expand its clinical development and manufacturing program into late-stage settings (Form 6-K)	Immutep completes a A$60 million placement to expand its clinical development and manufacturing program into late-stage settings Sydney, Australia - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or Company), is pleased to announce that ...
Jun 21, 2021	IMMUTEP LIMITED Immutep : to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy	ASX/Media Release Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumours Expands the evaluation ...
Jun 21, 2021	IMMUTEP LIMITED Immutep : secures commitments for A$60 million through a two-tranche institutional placement to expand its clinical development and manufacturing program into late-stage settings	Not for release to U.S. wire services or distribution in the United States or to U.S. Persons ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 21 June 2021 Immutep secures commitments for A$60 million through a two-tranche institutional pla...
Jun 21, 2021	IMMUTEP LIMITED Immutep : Capital Raising Presentation	Not for release to US wire services or distribution in the United States or to US Persons The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP) Capital Raising Presentation Notice: Forward Looking Statements The materi...
Jun 21, 2021	IMMUTEP LIMITED Immutep : Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings	Sydney, AUSTRALIA, June 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or Company), is pleased to announce that it has received commitments for a A$60 million two-tranche private placement of new ordinary sha...
Jun 10, 2021	IMMUTEP LIMITED Immutep : Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 Immunotherapy — PT to $9 from $6	Estimate Changes June 10, 2021 Biotechnology Matt Cross [email protected] Sales & Trading 888-543-4448 (NASDAQ: IMMP) Price $4.84 52 Week Range ($1.03 - $7.95) Price Target $9.00 Market Cap (mil) $349.30 Exchange rate 1US$ = 1.29 AUD...
Jun 7, 2021	IMMUTEP LIMITED Immutep : Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021 (Form 6-K)	Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021 • Encouraging activity signals from the combination of efti and avelumab with a response rate of 41.7% in different solid tumours (D...
Jun 7, 2021	IMMUTEP LIMITED Immutep : Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021 (Form 6-K)	Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021 • Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable overall response rate (ORR) together with favou...
Jun 6, 2021	IMMUTEP LIMITED Immutep : Goetzpartners securities - Efti combos move towards centre stage at ASCO	IMMUTEP LIMITED Biotechnology 5 June 2021 11:06 BST FLASH NOTE Immutep Limited (IMM-AU) Ei combos move towards centre stage at ASCO KEY TAKEAWAY Data presented at the ASCO further supports the use of eilagimod alpha ("ei") in P...
Jun 4, 2021	IMMUTEP LIMITED Immutep : Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021	Encouraging activity signals from the combination of efti and avelumab with a response rate of 41.7% in different solid tumours (DCR 50%) acc. to RECIST 1.1No selection of patients for immunogenic markers (e.g. PD-L1 expression levels, MSI ...
Jun 4, 2021	IMMUTEP LIMITED Immutep : Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares RemainUndervalued	EQUITY RESEARCH COMPANY UPDATE Biotechnology IMMP - NASDAQ June 4, 2021 Intraday Price 6/4/21 $5.21 Rating: Buy 12-Month Target Price: $8.00 52-Week Range: $1.03 - $7.95 Market Cap (M): 362.7 Shares O/S (M): 69.6 Float: NA Avg. Daily Volume...
Jun 2, 2021	IMMUTEP LIMITED Immutep : Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor	ASX/Media Release IMMUTEP SECURES SECOND EUROPEAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA - 2 June 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep&q...
Jun 1, 2021	IMMUTEP LIMITED Immutep : Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti	ASX/Media Release Immutep enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bintrafusp alfa New in...
May 20, 2021	IMMUTEP LIMITED Immutep : Goetzpartners securities - BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma	IMMUTEP LIMITED Biotechnology 20 May 2021 14:33 BST FLASH NOTE Immutep Limited (IMM-AU) BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma KEY TAKEAWAY Bristol Myers Squibb just announced that RELATIVITY-047 evaluang combinaon of its an...
Apr 30, 2021	IMMUTEP LIMITED Immutep : Corporate Connect - Efti a highly sort after compound for mono & combo Cancer treatment	Friday, 30 April 2021 COMPANY REVIEW Immutep Limited Efti a highly sort after compound for mono & combo Cancer treatment Immutep (IMM.AX) is one of the most promising drug developers listed on the ASX. A core competency is its unsurpass...
Apr 19, 2021	IMMUTEP LIMITED Immutep : receives A$1,155,055 R&D Tax Incentive	SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or the 'Company'), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government's R&D tax incentive program. The cas...
Apr 16, 2021	IMMUTEP LIMITED Immutep : Receives A$1,155,055 R&D Tax Incentive	ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 16 April 2021 Immutep receives A$1,155,055 R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company"), is pleased to a...
Apr 9, 2021	IMMUTEP LIMITED Immutep : Alliance Global Partners - FDA's Fast Track for Efti Suggests Regulators Echo Large Pharma Enthusiasm Surrounding LAG-3 Immunotherapy	Company Update April 8, 2021 Biotechnology Matt Cross [email protected] Sales & Trading 888-543-4448 (NASDAQ: IMMP) Price $3.18 52 Week Range ($0.68 - $7.95) Price Target $6.00 Market Cap (mil) $222.50 Exchange rate 1US$ = 1.31 AUD S...
Apr 8, 2021	IMMUTEP LIMITED Immutep : Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer	ASX/Media Release IMMUTEP ACHIEVES FAST TRACK DESIGNATION FROM US FDA FOR EFTI, A SOLUBLE LAG-3 PROTEIN, IN FIRST LINE RECURRENT/METASTATIC HEAD & NECK CANCER Fast Track designation opens the potential for expedited development and revi...
Apr 7, 2021	IMMUTEP LIMITED Immutep : Announces European Patent Grant For LAG525 Antibody In Combination Therapy	ASX/Media Release IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR LAG525 ANTIBODY IN COMBINATION THERAPY SYDNEY, AUSTRALIA - 7 April 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnolog...
Mar 26, 2021	IMMUTEP LIMITED Immutep : Goetzpartners securities - BMS Study Identifies LAG-3 - PD-1 as Potential 'Key Strategy'	IMMUTEP LIMITED Biotechnology 25 March 2021 20:27 GMT FLASH NOTE Immutep Limited (IMM-AU) OUTPERFORM BMS study idenﬁes LAG-3 - PD-1 as potenal "key strategy' Target Price AUD0.900 Current Price AUD0.345 KEY TAKEAWAY Bristol Myers Squ...
Mar 26, 2021	IMMUTEP LIMITED Immutep : Maxim Group - Bristol Brings LAG-3 to the Forefront in Checkpoints with First Positive P3 Trial; Bodes Well for Efti and LAG-3 Pipeline	EQUITY RESEARCH COMPANY UPDATE Biotechnology IMMP - NASDAQ Intraday Price 3/25/21 Rating: 12-Month Target Price: 52-Week Range: March 25, 2021 Bristol Brings LAG-3 to the Forefront in Checkpoints $3.30 Buy Pipeline $8.00 $0.53 - $7.95 Marke...
Dec 15, 2020	IMMUTEP LIMITED Immutep : Operational Update	ASX/Media Release OPERATIONAL UPDATE Efti clinical trial status updates Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 SYDNEY, AUSTRALIA - December 1...
Dec 15, 2020	Immutep : Operational Update	ASX/Media Release OPERATIONAL UPDATE Efti clinical trial status updates Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 SYDNEY, AUSTRALIA - December 1...
Nov 20, 2020	IMMUTEP LIMITED Immutep : Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete	EQUITY RESEARCH COMPANY UPDATE Biotechnology IMMP - NASDAQ November 19, 2020 Closing Price 11/18/20 $2.02 Rating: Buy 12-Month Target Price: $4.00 52-Week Range: $0.53 - $3.10 Market Cap (M): 99.6 Shares O/S (M): 49.3 Float: NA Avg. Daily V...
Nov 20, 2020	Immutep : Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete	EQUITY RESEARCH COMPANY UPDATE Biotechnology IMMP - NASDAQ November 19, 2020 Closing Price 11/18/20 $2.02 Rating: Buy 12-Month Target Price: $4.00 52-Week Range: $0.53 - $3.10 Market Cap (M): 99.6 Shares O/S (M): 49.3 Float: NA Avg. Daily V...
Sep 22, 2020	IMMUTEP LIMITED Immutep : Taylor Collison - BMS/Dragonfly deal drives valuation upgrade	Dr DENNIS HULME [email protected] +612 9377 1500 www.taylorcollison.com.au Immutep (IMM) BMS/Dragonfly deal drives valuation upgrade Our View There were no surprises in Immutep's FY20 results out overnight. Its LAG-3 drugs out-li...
Jul 23, 2020	IMMUTEP LIMITED Immutep : Quarterly Activities Report & Appendix 4C	ASX Announcement IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C Very encouraging data for efti from the ongoing Phase II TACTI-002 trial First complete disappearance of target lesion from a patient with second line HNSCC Progression-...
May 29, 2020	IMMUTEP LIMITED Immutep : Taylor Collison - Immutep (IMM) Leading not LAGging	Dr DENNIS HULME [email protected] +612 9377 1500 www.taylorcollison.com.au Immutep (IMM) Leading not LAGging Our View Immutep is developing therapies based on LAG-3 through in-house programs and licensing deals with big pharma. I...
Mar 9, 2020	Inovio files for $50M offering amid Covid-19 vaccine hunt; Zydus Cadila signs on with XOMA on IL-2 deal	→ Inovio, the company now building a DNA vaccine against the novel coronavirus, has filed for a $50 million equity offering. Touting its experience bringing a vaccine for MERS — a related virus — into Phase II, Inovio...
Oct 3, 2014	Prima BioMed Acquires Immutep for US$28M	Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) acquired Immutep SA, a Paris, France-based late stage biopharmaceutical company focused on immuno-oncology for approximately US$28M. The transaction is to be funded via an investment agreement with...
Feb 17, 2014	Novartis buys cancer immunotherapy startup co-founded by venture investors	Last year CoStim raised $10 million in a Series A round from MPM Capital and Atlas Ventures. Johnson & Johnson Development Corp. and Partners Innovation Fund also participated in the round. Although using patients’ T cells to help them ...
	Novartis buys cancer immunotherapy startup co-founded by venture investors	A biotechnology company formed by two MPM Capital managing directors to develop monoclonal antibody drugs to fight cancer has been acquired by Novartis, according to a company statement. The move follows Novartis’ deal with University of Pe...

Reviews 0

FAQ about Immutep

When was Immutep founded?

Immutep was founded in 1987.

How much funding has Immutep raised?

Immutep has raised $48.47M in total across 3 funding rounds.

What funding rounds has Immutep raised?

Parsers VC lists 3 funding rounds of Immutep, among them a funding round of $45.11M on Jun 21, 2021 and a funding round of $898.14K on Apr 16, 2021.

What has the press written about Immutep?

Parsers VC has collected 79 articles mentioning Immutep, among them “Immutep Receives A$2.6 million R&D Tax Incentive from French Government” (Dec 7, 2023) and “Immutep Completes A$80 Million Capital Raise” (Jun 27, 2023).

Is Immutep still active?

Yes, Immutep is active; its latest activity on Parsers VC dates from Mar 5, 2024.